Representatives of the Podolsk administration visit the Petrovax Pharm manufacturing complex
On 10 December, Vladimir Kravtsov, First Deputy Head of the Podolsk Urban District, and Irina Sorokina, Deputy Head of the Department for Investment Activities, Transport and Communications, visited the manufacturing site of Petrovax Pharm. During the visit, they discussed with the plant’s management the company’s 2025 results and achievements, prospects for further development in innovative R&D, and opportunities for new investment projects.
Regina Ibragimova, Director of the Petrovax Pharm plant, presented the key innovative projects being implemented at the facility. In particular, the technology transfer for meningococcal vaccine production is being completed this year, enabling protection against one of the most life-threatening infectious diseases. The company has extensive experience in the production and supply of influenza vaccines for both Russian and international markets, as well as a pneumococcal vaccine included in Russia’s National Immunization Schedule. Current production capacities are sufficient to manufacture over 3.5 million doses of meningococcal vaccine per year, fully covering both domestic demand and export potential.
Petrovax Pharm continues to systematically expand its portfolio of biotechnological products manufactured under a full-cycle model. Those include Fabagal® for the treatment of Fabry disease—the first orphan drug fully localized in Russia, starting from active substance synthesis—and Areima® for the treatment of nasopharyngeal, esophageal, and lung cancer, with technology transfer scheduled for completion this year. The projects are implemented in partnership with the N. F. Gamaleya National Research Center of Epidemiology and Microbiology.
The modern manufacturing and logistics complex of Petrovax Pharm is one of the leading biotechnological facilities in the Moscow Region. The manufacturing facility operates four production lines for pharmaceutical substance synthesis and the manufacture of advanced medicines and vaccines. The facility employs more than 400 staff members. Petrovax Pharm continues the digital transformation of its business processes: in 2025, the plant implemented the AXELOT WMS warehouse management system, which improved logistics efficiency and enabled end-to-end control of raw materials and finished products through full automation.
During the working meeting, Regina Ibragimova also outlined plans to expand production capacity. In 2026, the company plans to open a new manufacturing building dedicated to the production of active substances and genetically engineered medicinal products. Total investment in the construction project amounts to RUB 2 billion.
The visit marked an important step in strengthening partnership relations between Petrovax Pharm and the Podolsk administration, laying the groundwork for joint initiatives aimed at advancing innovative pharmaceutical development in the Moscow Region.
